Zevaquenabant
Product Specifications
UNSPSC Description
Zevaquenabant ((S)-MRI-1867) is a peripherally restricted, orally bioavailable dual cannabinoid CB1 receptor and inducible NOS antagonist. Zevaquenabant ameliorates obesity-induced chronic kidney disease (CKD)[1].
Target Antigen
Cannabinoid Receptor; NO Synthase
Type
Reference compound
Related Pathways
GPCR/G Protein;Immunology/Inflammation;Neuronal Signaling
Applications
Metabolism-protein/nucleotide metabolism
Field of Research
Metabolic Disease
Assay Protocol
https://www.medchemexpress.com/zevaquenabant.html
Solubility
10 mM in DMSO
Smiles
O=S(/N=C(N1N=C(C2=CC=C(Cl)C=C2)[C@@H](C3=CC=CC=C3)C1)/N=C(N)/C)(C4=CC=C(C(F)(F)F)C=C4)=O
Molecular Weight
547.98
References & Citations
[1]Udi S, et al. Dual inhibition of cannabinoid CB1 receptor and inducible NOS attenuates obesity-induced chronic kidney disease [published correction appears in Br J Pharmacol. 2021 Mar;178(5):1250]. Br J Pharmacol. 2020;177(1):110-127.
Shipping Conditions
Room temperature
Product Datasheet
http://file.medchemexpress.com/batch_PDF/HY-141411A/Zevaquenabant-DataSheet-MedChemExpress.pdf
Product MSDS
http://file.medchemexpress.com/batch_PDF/HY-141411A/
Clinical Information
No Development Reported
CAS Number
1998760-00-1
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items